Fatty Liver Disease: From Molecular Mechanisms to Novel Therapeutics
Special Issue Editor
Interests: alcoholic liver disease; non-alcoholic liver disease; intestinal microbiome; hepatitis C; COVID-19
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The liver has a unique blood supply from both portal and systemic sources. Portal blood is delivered directly via absorption from the GI tract. This includes substances that are both ingested and produced or metabolized by the intestinal microbiome.
Hepatic steatosis is a result of either alcohol ingestion or changes in hepatic metabolism linked to metabolic syndrome, including endogenous alcohol production. Steatosis may progress via steatohepatitis, fibrosis, or cirrhosis, and its complications include hepatocellular carcinoma.
As a result of the worldwide epidemic of obesity, metabolic-associated fatty liver disease (MAFLD) is common, with a prevalence of more than 30% in developed countries. Alcohol use has also increased, linked to the COVID-19 pandemic. The combination of these two drivers has had a major effect on alcoholic and metabolic-associated fatty liver disease.
This Special Issue aims to review the cellular and molecular mechanisms that contribute to the pathogenesis of hepatic steatosis, including the clinical features, diagnosis, and management of fatty liver disease. Submissions should explore both common mechanistic systems and the involvement of the intestinal microbiome.
Dr. Stephen Malnick
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- fatty liver disease
- metabolic-associated liver disease-MAFLD
- alcoholic liver disease
- non-alcoholic steatohepatitis
- alcohol and COVID-19
- cytokine storm
- microbiome
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
